|
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis |
Smith B, Cohn DE, Clements A, Tierney BJ, Straughn JM J |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Smith B, Cohn DE, Clements A, Tierney BJ, Straughn JM J. Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis. Gynecologic Oncology 2013; 130(3): 416-420 Indexing Status Subject indexing assigned by NLM MeSH Anemia /economics /etiology; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma /economics /therapy; Chemoradiotherapy /adverse effects /economics; Chemotherapy, Adjuvant /adverse effects /economics; Cisplatin /administration & Cost-Benefit Analysis; Deoxycytidine /administration & Disease-Free Survival; Female; Hospitalization /economics; Humans; Models, Econometric; Neutropenia /economics /etiology; Uterine Cervical Neoplasms /economics /therapy; derivatives /economics; dosage /analogs & dosage /economics AccessionNumber 22013022401 Date bibliographic record published 13/06/2013 |
|
|
|